Skip to main content

Advertisement

ADVERTISEMENT

Major Depressive Disorder News

Patient survey
News
11/06/2024
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive...
11/06/2024
Psych Congress Network
depression stock photo
News
11/04/2024
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Adjunctive treatment with the...
11/04/2024
Psych Congress Network
Psilocybin
News
10/08/2024
While intensive treatments with psilocybin and the serotonin reuptake inhibitor (SSRI) escitalopram were associated with long-term improvements in major depressive disorder (MDD) symptom severity, recent phase 2 double-blind, randomized,...
While intensive treatments with psilocybin and the serotonin reuptake inhibitor (SSRI) escitalopram were associated with long-term improvements in major depressive disorder (MDD) symptom severity, recent phase 2 double-blind, randomized,...
While intensive treatments with...
10/08/2024
Psych Congress Network

Advertisement

brain netw
News
09/05/2024
Patients with a particular cognitive biotype of treatment-resistant depression are more likely to experience improvement with TMS compared with other patients, study finds.
Patients with a particular cognitive biotype of treatment-resistant depression are more likely to experience improvement with TMS compared with other patients, study finds.
Patients with a particular...
09/05/2024
Psych Congress Network
Doctor and patient
News
08/01/2024
Antidepressant prescribing patterns and outcomes for patients with MDD vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.
Antidepressant prescribing patterns and outcomes for patients with MDD vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.
Antidepressant prescribing...
08/01/2024
Psych Congress Network
Combining TMS or tDCS With Certain Medications May Reduce MDD Symptoms
News
07/16/2024
Combining certain medications or psychotherapy with TMS or tDCS may decrease symptoms of MDD, though some limitations still exist, according to a review published in the Harvard Review of Psychiatry. 
Combining certain medications or psychotherapy with TMS or tDCS may decrease symptoms of MDD, though some limitations still exist, according to a review published in the Harvard Review of Psychiatry. 
Combining certain medications or...
07/16/2024
Psych Congress Network

Advertisement

ketamine brain image
News
05/14/2024
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and “inadequate outcomes” with monoamine-based therapies, a Toronto-based research team investigated novel alternatives for TRD.
To address the challenges and...
05/14/2024
Psych Congress Network
woman looking down on phone
News
05/07/2024
The prevalence of MDD at a major health system was 3 times higher in female patients with Huntington disease (HD) than in male patients, according to a poster presentation APA Annual Meeting.
The prevalence of MDD at a major health system was 3 times higher in female patients with Huntington disease (HD) than in male patients, according to a poster presentation APA Annual Meeting.
The prevalence of MDD at a major...
05/07/2024
Psych Congress Network
FDA approval stamp
News
04/30/2024
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Rejoyn has been FDA approved as...
04/30/2024
Psych Congress Network

Advertisement

Tinnitus
News
03/06/2024
Multilocus rTMS reduced tinnitus symptom severity in both patients with and without comorbid MDD in a recent open-label treatment study.
Multilocus rTMS reduced tinnitus symptom severity in both patients with and without comorbid MDD in a recent open-label treatment study.
Multilocus rTMS reduced tinnitus...
03/06/2024
Psych Congress Network

Advertisement